Adverse events associated with efgartigimod use

We collected and analyzed efgartigimod alfa-related reports from the FAERS database from the first quarter of 2022 through the second quarter of 2024. Disproportionality analysis was used in data mining to quantify efgartigimod alfa-related AE signals.
In addition to the large number of AE signals associated with infections found during the clinical trial phase, this study also identified some unexpectedly important AEs, such as inappropriate schedule of product administration and nephrolithiasis.